Trending Topic

Breast Cancer
29 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant […]

Julie Graff, ESMO 2019 – KEYNOTE-641 study in prostate cancer

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 8th 2019

We met with Julie Graff (Knight Cancer Institute) at ESMO 2019 to discuss unmet needs in the treatment of metastatic castration-resistant prostate cancer and KEYNOTE-641 (NCT03834493), a phase III study of pembrolizumab plus enzalutamide in this patient population.

Questions
1.     What are the current unmet needs in the treatment of metastatic castration-resistant prostate cancer (mCRPC) with androgen receptor inhibitors? (0:05)
2.     Could you tell us a little about the aims and design of the KEYNOTE-641 study? (0:50)
3.     What are the eligibility criteria for this study? (1:23)
4.     How can we overcome the challenge of identifying biomarkers predictive of response to pembrolizumab? (1:55)
5.     What other combined therapeutic approaches involving androgen receptor inhibitors are being investigated in the treatment of mCRPC? (2:51)

Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.

Speaker disclosure: Julie Graff has received travel expenses from Sanofi.

touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup